Gut Microbiome in AP Naive

This ongoing clinical trial, based at the Centre for Addiction and Mental Health, is investigating what happens to the gut microbiome in young people who are starting antipsychotic (AP) medications for the first time — a group described as 'AP naive.' Antipsychotics are the primary treatment for schizophrenia and are increasingly prescribed off-label in youth, but they carry serious metabolic risks including weight gain and diabetes. Researchers suspect the gut microbiome — the ecosystem of trillions of bacteria living in our intestines — may be a key mechanism through which antipsychotics drive these metabolic changes. The study tracks participants longitudinally, measuring shifts in gut microbial communities alongside metabolic markers like insulin sensitivity, blood glucose, lipids, and body weight. A notable secondary focus is cognition and behavior, reflecting the growing understanding of the gut-brain axis. Because youth are disproportionately vulnerable to antipsychotic-induced metabolic harm compared to adults, this population is a critical target. If the gut microbiome is confirmed as a mediating mechanism, it could open the door to microbiome-targeted interventions — such as dietary changes, probiotics, or other strategies — to reduce metabolic harm without sacrificing psychiatric benefit.

• This is an active, not-yet-completed trial (status: ACTIVE_NOT_RECRUITING as of 2026-05-27); primary outcome data are not yet published in the abstract, so specific effect sizes are not available at this stage.
• The study hypothesizes measurable changes in gut microbiome composition over the course of antipsychotic treatment that will correlate with deteriorating metabolic markers including weight gain, impaired glucose tolerance, insulin resistance, altered adipokines, GLP-1, and lipid profiles.
• A secondary hypothesis posits that antipsychotic-induced gut dysbiosis will also associate with changes in cognition and behavior, consistent with a gut-brain axis mechanism, though confirmatory data await publication.

This is a longitudinal, prospective cohort study (with randomized controlled trial elements per the AI rationale) enrolling antipsychotic-naive participants — likely youth with a schizophrenia-spectrum diagnosis — at the Centre for Addiction and Mental Health. Participants are assessed at multiple time points before and after initiating antipsychotic treatment, with gut microbiome profiling conducted alongside metabolic measures (glucose tolerance, insulin sensitivity, adipokines, GLP-1, lipids, fasting glucose, body weight) and cognitive assessments. The study is registered on ClinicalTrials.gov (NCT03414151) with a projected completion context extending to 2026. Sample size and specific antipsychotic agents studied are not detailed in the available abstract; methods confidence is therefore moderate and flagged as best-effort.

Because results have not yet been published, it is not possible to evaluate effect sizes, directionality of microbiome changes, or which specific microbial taxa are implicated — all key details for clinical translation. The study is observational in its microbiome component, meaning that correlations between dysbiosis and metabolic change cannot confirm causality without experimental manipulation (e.g., microbiome transplant or targeted probiotic intervention). The focus on a single clinical site may limit generalizability across diverse ethnic populations, dietary backgrounds, and antipsychotic drug classes. The next clarifying experiment would be a mechanistic trial — such as the AKK supplementation approach explored in related work — that tests whether correcting AP-induced dysbiosis actually prevents metabolic harm.

This trial extends [§100], which argues for an ecological and causal framework when interpreting microbiome associations with complex diseases like schizophrenia and metabolic dysfunction — the CAMH study operationalizes exactly that framework in a longitudinal human cohort. It parallels [§72], where gut microbiota remodeling was tracked as a mechanism of metabolic change (in that case beneficial, post-bariatric surgery), providing a useful contrast: both studies treat the microbiome as a dynamic mediator of metabolic phenotype, but in opposite directions of metabolic trajectory. The study also parallels [§86], which used deep metagenomic sequencing to link gut microbiota and metabolome signatures with cognitive impairment in a post-stroke cohort, reinforcing that gut-brain axis mechanisms detectable via microbiome profiling may generalise across neuropsychiatric contexts. Together, these relationships position the CAMH trial as a mechanistic bridge between ecological microbiome science [§100] and intervention-ready targets [§72], with cognitive outcomes adding a dimension explored more fully in neuro-adjacent microbiome work [§86].

• Microbiota remodeling after bariatric surgery: Procedure-specific dynamics and metabolic implications
  Direct mechanistic mirror: microbiota remodeling tracked longitudinally as a driver of metabolic change in a clinical population, but in the opposite direction (metabolic improvement post-bariatric surgery vs. metabolic harm post-antipsychotic), making comparison highly instructive for identifying shared vs. drug-specific microbial signatures.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Provides the theoretical backbone — ecological and causal reasoning for microbiome research — that this trial's design implicitly relies on; reading both clarifies what standards of evidence are needed to move from correlation to mechanism.
• Integrated gut microbiota and metabolome signatures revealed by deep metagenomic sequencing in post-stroke cognitive impairment with type 2 diabetes
  Same dual-outcome design (microbiome + cognition) in a different neuropsychiatric population (post-stroke cognitive impairment), offering a benchmark for what gut-brain axis signals look like in practice and which metagenomic methods yield actionable results.
• The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
  Examines a dietary fiber intervention's effect on both carbohydrate metabolism and gut microbiota in a metabolic disease context — directly relevant as a potential intervention model if this trial confirms that AP-induced dysbiosis drives glucose dysregulation.
• A single-strain dropout screen reveals mechanistic links between microbial ecology and metabolism
  Single-strain dropout screen revealing mechanistic links between microbial ecology and metabolism offers granular, mechanistic detail about which specific microbial players drive metabolic outcomes — a useful companion for interpreting taxa-level findings once this trial's data are published.